BioBel Life
Sciences

Endocrine, Metabolic & Longevity Medicine Research

Bridging Holistic Wellbeing & Evidence-Based Medicine

Contact Us Investment Opportunities

$35B

Global Market Size

1.2M

Australian Market

ABOUT US

Welcome To BioBel Life
Sciences Pty Ltd

Australian biotechnology company pioneering clinical & regulatory innovation in hormonal, metabolic, and longevity medicine.

Founded with a mission to bridge holistic wellbeing and scientific rigour, BioBel develops, validates, scales regulated therapies that restore physiological balance through the endocrine system.

  • Our Mision
  • Our Commitment
  • Our Vision

More About Us

What we do

Flagship Programme: BioBel-E Dual-Capsule Bioidentical Therapy

BioBel’s flagship therapeutic program supports menopausal wellbeing through an innovative dual-capsule bioidentical hormone therapy designed to mirror the body’s natural rhythms.

AM Capsule

Estradiol (E2) + Estriol (E3)

Morning formulation carefully designed to support daytime hormonal needs & symptom management. This combination mirrors the body’s natural oestrogen patterns, providing targeted relief when women need it most during active hours.

Learn More

PM Capsule

Micronised Progesterone (P4)

Evening formulation expertly engineered to maintain critical endometrial protection and support natural sleep cycles. The timing optimises progesterone’s calming effects whilst ensuring proper uterine health.

Learn More

This dual-capsule system is meticulously designed to replicate physiologic hormone rhythms whilst maintaining critical endometrial protection, offering women a therapy that works in harmony with their body’s natural processes.

Roadmap

Clinical Development Pathway

BioBel’s clinical development pathway aligns with TGA and FDA frameworks, integrating patient-centred design and evidence-based methodology.

BioBel’s clinical development programme adheres to the highest international standards, with rigorous protocols designed to demonstrate both efficacy and safety. Our Phase 2 trial design reflects best practices in endocrine clinical research, incorporating patient-centred endpoints and comprehensive safety monitoring.

  • Phase 2 Trial Design

    Randomised, double-blind, placebo-controlled study of postmenopausal women aged 45-65 years. Study design incorporates adaptive elements to optimise dose -finding whilst maintaining statistical rigour.

  • Primary Endpoint

    Reduction in vasomotor symptom frequency and severity as measured by validated patient-reported outcome instruments, with continuous digital tracking to capture real-world symptom patterns.

  • Secondary Endpoints

    Comprehensive assessment of sleep quality, mood stability, metabolic markers, and safety including bone density, cardiovascular biomarkers, and quality of life measures across multiple validated scales.

  • Manufacturing Partnership

    Production via GMP-certified partners in Australia and the European Union, ensuring supply chain redundancy and regulatory compliance across multiple jurisdictions.

  • Trial Initiation

    Q1 2026 – First patient enrolled, with recruitment across multiple sites in Australia and potential expansion to New Zealand and Southeast Asian markets.

Regulatory Strategy: BioBel’s clinical development aligns with both FDA IND and TGA CTN frameworks, positioning the programme for potential multi-market approval pathways including Australia, United States, European Union, and key Asian markets.

Research

Expanded Research Pipeline

Beyond bioidentical hormone therapy, BioBel’s R&D portfolio strategically expands into metabolic optimisation, neuroendocrine ageing, reproductive longevity, and precision diagnostics. Each programme addresses critical unmet needs in the global endocrine therapeutics landscape, with clear pathways to clinical validation and commercialisation.

Dual-Capsule Bioidentical Hormone Therapy

  • BioBel-E
  • Status: Phase 2 Ready

Flagship programme targeting menopausal & andropausal health through circadianaligned hormone delivery…

Hormonal-Metabolic Optimisation

  • BioBel-M
  • Status: Pre-clinical

Novel therapeutic approach targeting insulin resistance and weight regulation through strategic hormone…

Neuroendocrine Support Formulations

  • BioBel-N
  • Status: Pre-clinical

DHEA and pregnenolone formulations supporting cognition, mood stability, and sleep architecture…

Reproductive Longevity Platform

  • BioBel-R
  • Status: Discovery

Innovative peptide-hormone hybrid therapeutics for ovarian and testicular longevity. Aims to extend reproductive..

AI-Powered Hormone Diagnostics

  • BioBel-D
  • Status: Development

Machine learning platform for individualised therapy optimisation. Integrates multi-timepoint hormone…

learn more